$6.61
7.03% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US87978U1088
Symbol
TPST
Sector
Industry

Tempest Therapeutics Inc Stock price

$6.61
-0.18 2.65% 1M
-3.79 36.44% 6M
-4.24 39.07% YTD
-32.78 83.22% 1Y
-397.04 98.36% 5Y
-108,949.64 99.99% 10Y
-21,930.89 99.97% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.50 7.03%
ISIN
US87978U1088
Symbol
TPST
Sector
Industry

Key metrics

Market capitalization $24.34m
Enterprise Value $7.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.09
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-44.99m
Free Cash Flow (TTM) Free Cash Flow $-34.14m
Cash position $21.51m
EPS (TTM) EPS $-13.03
P/E forward negative
Short interest 3.02%
Show more

Is Tempest Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Tempest Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Tempest Therapeutics Inc forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Tempest Therapeutics Inc forecast:

Hold
100%

Financial data from Tempest Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
7% 7%
-
- Research and Development Expense 32 32
85% 85%
-
-45 -45
53% 53%
-
- Depreciation and Amortization 0.37 0.37
9% 9%
-
EBIT (Operating Income) EBIT -45 -45
52% 52%
-
Net Profit -45 -45
51% 51%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tempest Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tempest Therapeutics Inc Stock News

Neutral
GlobeNewsWire
3 days ago
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale in a registered direct offering of 739,000...
Neutral
GlobeNewsWire
9 days ago
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory designations were granted following strong positive results from a global randomized Phase 1b/2 study in first-line HCC demonstrating superior outcomes for amezalpat combination therapy across multiple st...
Neutral
GlobeNewsWire
about one month ago
BRISBANE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2025 and provided a corporate update.
More Tempest Therapeutics Inc News

Company Profile

Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.

Head office United States
CEO Stephen Brady
Employees 24
Founded 2011
Website www.tempesttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today